At the time of writing, NewAmsterdam Pharma Company NV [NAMS] stock is trading at $23.62, up 8.70%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NAMS shares have gain 5.31% over the last week, with a monthly amount glided 17.98%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NewAmsterdam Pharma Company NV [NASDAQ: NAMS] stock has seen the most recent analyst activity on July 17, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $27. Previously, Citigroup started tracking the stock with Buy rating on June 17, 2025, and set its price target to $42. On June 10, 2025, Stifel initiated with a Buy rating and assigned a price target of $44 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $42 on June 04, 2025. H.C. Wainwright initiated its recommendation with a Buy and recommended $48 as its price target on December 30, 2024. In a note dated March 14, 2024, Scotiabank initiated an Sector Outperform rating and provided a target price of $35 on this stock.
For the past year, the stock price of NewAmsterdam Pharma Company NV fluctuated between $14.06 and $27.29. Currently, Wall Street analysts expect the stock to reach $41 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $23.62 at the most recent close of the market. An investor can expect a potential return of 73.58% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
According to NewAmsterdam Pharma Company NV [NASDAQ:NAMS], the company’s sales were 47.14M for trailing twelve months, which represents an 112.56% jump. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -4.02%, Pretax Profit Margin comes in at -3.97%, and Net Profit Margin reading is -3.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.33 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that NewAmsterdam Pharma Company NV [NASDAQ:NAMS] has a current ratio of 19.98. Also, the Quick Ratio is 19.98, while the Cash Ratio stands at 18.29. Considering the valuation of this stock, the price to sales ratio is 56.25, the price to book ratio is 3.41.
Transactions by insiders
Recent insider trading involved Kling Douglas F, Chief Operating Officer, that happened on Jul 16 ’25 when 51043.0 shares were sold. Chief Operating Officer, Kling Douglas F completed a deal on Jul 15 ’25 to sell 47569.0 shares. Meanwhile, Affiliate NAP PoolCo B.V. bought 1.43 million shares on Jul 14 ’25.
